Products
Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
*Further life cycle opportunities, including severe influenza, AI: Artificial Intelligence; CRS: Cytokine release Syndrome; GLP-1: Glucagon-like Receptor-1; MAPK: Mitogen Activated protein Kinase